Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A method for the detection of a polymorphism in OATPF in a human which method comprises determining the sequence of the human at any one of the following positions:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17.

2. (Original) A method according to claim 1 wherein the polymorphism is further defined as:
polymorphism at position 11-16 is presence of TAAAAA and/or insertion of ACTTTGAAAG in lieu thereof;
polymorphism at position 86 is presence of A and/or G;
polymorphism at position 505 is presence of C and/or T;
polymorphism at position 1339 is presence of A and/or G;
polymorphism at position 1991 is presence of A and/or T; and
polymorphism at position 8 is presence of Asn and/or Asp.

3. (Currently amended) A method according to claim 1 ~~or 2~~ wherein the method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism.

4. (Currently amended) Use of a method defined in ~~any of claims 1-3~~ claim 1 to assess the pharmacogenetics of a drug transportable by OATPF.

5. (Original) A polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic variant selected from any of the following:

Region	**variant**	**Position**
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-20 (SEQ ID NO: 15)

6. (Original) An allele specific primer capable of detecting an OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15, and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

7. (Original) An allele specific oligonucleotide probe capable of detecting a OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15 and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

8. (Currently amended) A diagnostic kit comprising ~~an allele-specific oligonucleotide probe of claim 7 and/or an~~ the allele-specific primer of claim 6.

9. (Original) A method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:

i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of:

position 11-16 of SEQ ID NO: 15;

positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;

position 8 of SEQ ID NO: 17; and

ii) administering an effective amount of the drug.

10. (Original) Use of a drug transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism at one of the following positions:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17.

11. (Original) An allelic variant of human OATPF polypeptide comprising an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

12. (Original) An antibody specific for an allelic variant of human OATPF polypeptide as described herein having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

13. (Original) A diagnostic kit comprising an antibody of claim 12.

14. (New) A diagnostic kit comprising the allele specific oligonucleotide probe of claim 7.